Wednesday, September 27, 2023 3:56:56 PM
In this economic environment I am not sure remaining on the NASDAQ is all that important especially if you believe a RS will bring an end to TTOO. It will take months for sales to be
made and deals signed with the FDA just now giving the green light. Why not just go back to the OTC and let the business grow until it reaches $2.00 and then reapply for the NASDAQ. This way we keep our shares, there is no share restructuring, and TTOO avoids the certain demise of a RS. Just canceling the RS will raise the SP.. It won't be. That long for orders to come in. All of this is really just a timing problem. Being on the NASDAQ is no big deal as there is just as much corruption here as the OTC.
Recent TTOO News
- T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/17/2024 08:05:00 PM
- T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/15/2024 11:00:00 AM
- T2 Biosystems Announces CRG’s Conversion from Preferred Stock to Common Stock • GlobeNewswire Inc. • 05/14/2024 09:00:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/14/2024 08:55:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:43:56 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/13/2024 11:21:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 10:19:50 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/07/2024 11:46:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:57:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:48:00 PM
- T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease • GlobeNewswire Inc. • 05/07/2024 01:00:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/06/2024 09:27:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:24:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 09:19:02 PM
- T2 Biosystems Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/06/2024 08:34:38 PM
- T2 Biosystems Announces Commercial Expansion Through Middle East Distributor • GlobeNewswire Inc. • 05/06/2024 08:34:16 PM
- T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity • GlobeNewswire Inc. • 05/06/2024 08:29:41 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/06/2024 11:48:38 AM
- T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024 • GlobeNewswire Inc. • 04/24/2024 01:00:00 PM
- T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity • GlobeNewswire Inc. • 04/11/2024 08:05:00 PM
- T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates • GlobeNewswire Inc. • 03/20/2024 11:30:00 AM
- T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates • GlobeNewswire Inc. • 03/19/2024 01:00:00 PM
- T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel • GlobeNewswire Inc. • 03/18/2024 01:00:00 PM
- T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement • GlobeNewswire Inc. • 03/12/2024 01:00:00 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONG • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM